2026 Cem Gabay: Immunology Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Immunology	88	1141	1033	29	25	408	45294
Medicine	88	12921	12160	179	172	417	45342

Overview

Cem Gabay is affiliated with the University of Geneva in Switzerland and works primarily within the fields of Medicine and Immunology and Microbiology. Their research spans various subfields, including Immunology, Rheumatology, Molecular Biology, Hematology, and Infectious Diseases.

Their main research topics cover a range of immune-related conditions and mechanisms, including:

Inflammasome and immune disorders
Autoimmune and Inflammatory Disorders Research
Rheumatoid Arthritis Research and Therapies
Systemic Lupus Erythematosus Research
IL-33, ST2, and ILC Pathways
Monoclonal and Polyclonal Antibodies Research
Immune Cell Function and Interaction

Their publication record includes articles in various scientific journals and venues. Frequent publication venues for their work include:

Revue Médicale Suisse
Arthritis & Rheumatology
The Journal of Immunology
bioRxiv (Cold Spring Harbor Laboratory)
Lara D. Veeken

Some of the recent papers by Cem Gabay are:

Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial, 2020, The Lancet
Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis, 2020, Arthritis Research & Therapy
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries, 2020, Lara D. Veeken
Impact of Acute Inflammation on Cytochromes P450 Activity Assessed by the Geneva Cocktail, 2020, Clinical Pharmacology & Therapeutics
Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland, 2020, RMD Open

Cem Gabay frequently collaborates with a number of co-authors, including:

Charlotte Girard
Axel Finckh
Emiliana Rodriguez
Denis Mongin
Céline Lamacchia

Best Publications

Acute-phase proteins and other systemic responses to inflammation.

Unknown

7435
Citations
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

Josef S Smolen;Robert Landewé;Ferdinand C Breedveld;Maya Buch;Maya Buch

5227
Citations
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

Josef S. Smolen;Robert Landewé;Ferdinand C Breedveld;Maxime Dougados

2432
Citations
Interleukin-6 and chronic inflammation.

Cem Gabay

1817
Citations
INTERLEUKIN-1 RECEPTOR ANTAGONIST: Role in Biology

William P. Arend;Mark Malyak;Carla J. Guthridge;Cem Gabay

1571
Citations
IL‐1, IL‐18, and IL‐33 families of cytokines

William P. Arend;Gaby Palmer;Cem Gabay

1252
Citations
IL-1 pathways in inflammation and human diseases

Cem Gabay;Céline Lamacchia;Gaby Palmer

1105
Citations
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

Cem Gabay;Paul Emery;Ronald van Vollenhoven;Ara Dikranian

817
Citations
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

J. S. Smolen;R. Landewé;F. C. Breedveld;M. Dougados

558
Citations
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis

Danielle M. Gerlag;Karim Raza;Lisa G M van Baarsen;Elisabeth Brouwer

552
Citations
The interleukin (IL)-1 cytokine family--Balance between agonists and antagonists in inflammatory diseases

Jennifer Palomo;Damien Dietrich;Praxedis Martin;Gaby Palmer

526
Citations
Leptin Signaling Deficiency Impairs Humoral and Cellular Immune Responses and Attenuates Experimental Arthritis

Nathalie Busso;Alexander So;Véronique Chobaz-Péclat;Carole Morard

456
Citations
Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis.

Gaby Palmer;Dominique Talabot-Ayer;Céline Lamacchia;Dean Toy

419
Citations
Leptin deficiency enhances sensitivity to endotoxin-induced lethality

Raffaella Faggioni;Giamila Fantuzzi;Cem Gabay;Arthur Moser

404
Citations
IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin?

Christoph A. Meier;Elisabetta Bobbioni;Cem Gabay;Françoise Assimacopoulos-Jeannet

396
Citations
Prevotella copri in individuals at risk for rheumatoid arthritis.

Deshire Alpizar-Rodriguez;Till Robin Lesker;Achim Gronow;Benoît Gilbert

396
Citations
Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells.

David Moulin;Olivier Donzé;Dominique Talabot-Ayer;Françoise Mézin

388
Citations
Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome

Eric S. Weiss;Charlotte Girard-Guyonvarc’h;Dirk Holzinger;Dirk Holzinger;Adriana A. de Jesus

384
Citations
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics

Glynn Dennis;Cécile T J Holweg;Sarah K Kummerfeld;David F Choy

382
Citations
IL-36R ligands are potent regulators of dendritic and T cells

Solenne Vigne;Gaby Palmer;Céline Lamacchia;Praxedis Martin

363
Citations
Anti‐cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis

S Bas;S Genevay;O Meyer;C Gabay

358
Citations
CD14 Is an Acute-Phase Protein

Sylvette Bas;Benoit R. Gauthier;Ursula Spenato;Sybille Stingelin

343
Citations
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial (vol 381, pg 1541, 2013)

C. Gabay;P. Emery;R. van Vollenhoven

19
Citations

Frequent Co-Authors

Gaby Palmer University of Geneva

Karel Pavelka Charles University

Tore K. Kvien University of Oslo

Paul Emery University of Leeds

Juan J. Gomez-Reino University of Santiago de Compostela

Ronald F. van Vollenhoven University of Amsterdam

Maxime Dougados Hôpital Cochin

Gerd R. Burmester Charité - University Medicine Berlin

Jean-Michel Dayer University of Geneva

Dominique Baeten University of Amsterdam

External Links

Personal website of Cem Gabay

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

Studying Immunology in the USA can open the door to diverse healthcare and research careers, often intersecting with nursing and clinical sciences. Many students explore accelerated pathways to combine their immunology background with advanced nursing roles. For example, those interested in nursing can benefit from enrolling in accelerated RN to NP programs, which fast-track registered nurses to nurse practitioner roles.

For nurses aiming to specialize further, acute care certification for FNP professionals offers a focused credential essential for managing critically ill patients, aligning well with immunology expertise related to immune responses and infectious diseases.

Prospective students without a nursing background might consider exploring the best online RN programs for non nurses. These programs provide a solid clinical foundation while offering flexibility for those transitioning from science-based fields like immunology.

Additionally, those looking for quicker entry into nursing can look into the easiest ABSN programs to get into. These accelerated programs allow individuals to earn a Bachelor of Science in Nursing efficiently, creating more career options in healthcare, including immunology-related clinical settings.